Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported revenue was CNY 37,829.6 million compared to CNY 35,488.15 million a year ago. Net income was CNY 237.61 million compared to CNY 352.51 million a year ago.

Basic earnings per share from continuing operations was CNY 0.0481 compared to CNY 0.0713 a year ago. Diluted earnings per share from continuing operations was CNY 0.0481 compared to CNY 0.0713 a year ago.